CY1121284T1 - Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων - Google Patents

Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων

Info

Publication number
CY1121284T1
CY1121284T1 CY20191100248T CY191100248T CY1121284T1 CY 1121284 T1 CY1121284 T1 CY 1121284T1 CY 20191100248 T CY20191100248 T CY 20191100248T CY 191100248 T CY191100248 T CY 191100248T CY 1121284 T1 CY1121284 T1 CY 1121284T1
Authority
CY
Cyprus
Prior art keywords
antibiotics
treatment
compound
diseases combined
diseases
Prior art date
Application number
CY20191100248T
Other languages
English (en)
Inventor
Youe-Kong Shue
Farah Kondori Babakhani
Franklin W. Okumu
Pamela Suzanne Sears
Starr Louise Miller-Shangle
Robert Brian Walsh
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1121284T1 publication Critical patent/CY1121284T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση αυτή αφορά στη θεραπεία ή την πρόληψη ασθενειών που συνδυάζονται με τη χρήση αντιβιοτικών ή χημειοθεραπείες καρκίνου ή αντι-ιικές θεραπείες όπως κολίτιδας, ψευδομεμβρανώδους κολίτιδας, σχετικής με αντιβιοτικό διάρροιας και μολύνσεις λόγω C. difficile, C. perfringens, Staphylococcus είδη που συμπεριλαμβάνει ανθεκτικό σε μεθικιλλίνη Staphylococcus aureus (MRSA) ή Enterococcus που συμπεριλαμβάνει ανθεκτικούς σε βανκομυκίνη εντερόκοκκους (VRE) με Ένωση I.
CY20191100248T 2004-05-14 2019-02-28 Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων CY1121284T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57069704P 2004-05-14 2004-05-14
EP05748007A EP1765312B1 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics
PCT/US2005/016750 WO2005112990A2 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics

Publications (1)

Publication Number Publication Date
CY1121284T1 true CY1121284T1 (el) 2020-05-29

Family

ID=35428857

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100404T CY1117501T1 (el) 2004-05-14 2016-05-13 Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων
CY20191100248T CY1121284T1 (el) 2004-05-14 2019-02-28 Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100404T CY1117501T1 (el) 2004-05-14 2016-05-13 Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων

Country Status (17)

Country Link
US (2) US20070173462A1 (el)
EP (4) EP1765312B1 (el)
JP (2) JP5734545B2 (el)
AT (1) ATE516024T1 (el)
BR (1) BRPI0511119A (el)
CA (2) CA2566687C (el)
CY (2) CY1117501T1 (el)
DK (3) DK2305244T3 (el)
ES (4) ES2395404T3 (el)
HU (3) HUE027757T2 (el)
LT (1) LT2305245T (el)
MX (2) MXPA06013245A (el)
PL (3) PL2305244T3 (el)
PT (2) PT2305245T (el)
SI (2) SI2070530T1 (el)
TR (1) TR201902533T4 (el)
WO (1) WO2005112990A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
CN101128114B (zh) * 2005-01-31 2012-03-28 浩鼎生技公司 18元环大环化合物及其类似物
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
EP1940417A4 (en) * 2005-10-21 2010-07-07 Optimer Pharmaceuticals Inc METHOD FOR TREATING DIARRHOE IN CONNECTION WITH CLOSTRIDIUM DIFFICILE
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
US20110008303A1 (en) * 2008-03-17 2011-01-13 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) * 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
JP2013510900A (ja) * 2009-11-17 2013-03-28 ピラマル・ライフ・サイエンシーズ・リミテッド 炎症性疾患治療のための大環状ラクトン誘導体の使用
WO2011082218A1 (en) * 2009-12-31 2011-07-07 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
AU2011255630B2 (en) * 2010-05-18 2015-04-30 Merck Sharp & Dohme Llc Treatment of Clostridium difficile infection in patients undergoing antibiotic therapy
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
TR201815891T4 (tr) * 2014-05-09 2018-11-21 Astellas Pharma Europe Ltd Tiakumisin bileşiği için tedavi rejimi.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
IN186245B (el) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
AU2003220525A1 (en) * 2002-03-29 2003-10-20 Abgenix, Inc. Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
WO2004014295A2 (en) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
EP1765312A2 (en) 2007-03-28
TR201902533T4 (tr) 2019-03-21
JP2007537290A (ja) 2007-12-20
CY1117501T1 (el) 2017-04-26
EP2305244B1 (en) 2016-10-12
CA2776682A1 (en) 2005-12-01
JP5734545B2 (ja) 2015-06-17
PL2305245T3 (pl) 2019-05-31
MXPA06013245A (es) 2007-05-09
WO2005112990A2 (en) 2005-12-01
DK2070530T3 (da) 2016-05-17
ES2395404T3 (es) 2013-02-12
ES2565609T3 (es) 2016-04-05
WO2005112990A3 (en) 2006-01-05
ATE516024T1 (de) 2011-07-15
SI2305245T1 (sl) 2019-04-30
EP2070530A1 (en) 2009-06-17
HUE031581T2 (en) 2017-07-28
ES2713954T3 (es) 2019-05-24
EP1765312A4 (en) 2007-08-22
LT2305245T (lt) 2019-03-12
CA2566687A1 (en) 2005-12-01
JP2012197309A (ja) 2012-10-18
CA2566687C (en) 2012-07-24
MX344601B (es) 2016-12-20
PL2070530T3 (pl) 2016-06-30
PL2305244T3 (pl) 2017-04-28
EP1765312B1 (en) 2011-07-13
US20070173462A1 (en) 2007-07-26
ES2608046T3 (es) 2017-04-05
JP6101010B2 (ja) 2017-03-22
EP2070530B1 (en) 2016-02-17
SI2070530T1 (sl) 2016-05-31
BRPI0511119A (pt) 2007-11-27
EP2305245A1 (en) 2011-04-06
DK2305245T3 (en) 2019-03-25
EP2305244A1 (en) 2011-04-06
PT2305244T (pt) 2016-12-29
PT2305245T (pt) 2019-03-19
DK2305244T3 (en) 2017-01-30
HUE027757T2 (en) 2016-11-28
US20130274175A1 (en) 2013-10-17
HUE043945T2 (hu) 2019-09-30
EP2305245B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
CY1121284T1 (el) Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
GT200600114A (es) Derivados de ciclopropanocarboxamida
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
SV2006002187A (es) Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590)
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
NZ597046A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
CY1108196T1 (el) Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα
CL2008002384A1 (es) Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
BRPI0615614A2 (pt) compostos orgánicos
BRPI0607723A2 (pt) isotiazoloquinolonas e compostos relacionados como agentes antiinfecciosos
GT200500308A (es) Nonadepsipeptidos acilados ii
ATE427315T1 (de) Neue makrolide
GT200700105A (es) Inhibidor del factor xa
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
BR0312211A (pt) difluortioacetamidas de oxazolidinonas como agentes antibacterianos
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
ECSP088132A (es) INHIBIDORES DE 6-ALQUILIDENO-PENEME B-LACTAMASA BICÍCLICOS Y COMBINACIÓN ANTIBIÓTICA DE ß-LACTAMA: UN ANTIBIÓTICO DE AMPLIO ESPECTRO